Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $20.20 Consensus PT from Brokerages

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has received an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and eleven have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $20.20.

Several equities research analysts recently commented on ORIC shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Oric Pharmaceuticals in a report on Monday, March 9th. Evercore started coverage on shares of Oric Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $25.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research note on Thursday, January 22nd. Wells Fargo & Company upped their price target on shares of Oric Pharmaceuticals from $19.00 to $25.00 and gave the stock an “overweight” rating in a research report on Monday, December 8th. Finally, Wall Street Zen raised shares of Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th.

Insider Buying and Selling at Oric Pharmaceuticals

In other Oric Pharmaceuticals news, insider Pratik S. Multani sold 10,720 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total transaction of $97,123.20. Following the completion of the transaction, the insider owned 68,149 shares of the company’s stock, valued at $617,429.94. This represents a 13.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Dominic Piscitelli sold 52,000 shares of Oric Pharmaceuticals stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $13.51, for a total value of $702,520.00. Following the completion of the sale, the chief financial officer directly owned 68,148 shares in the company, valued at $920,679.48. This represents a 43.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 106,814 shares of company stock valued at $1,199,135 over the last quarter. 5.55% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oric Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Federation des caisses Desjardins du Quebec grew its holdings in shares of Oric Pharmaceuticals by 100.0% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock worth $33,000 after buying an additional 2,000 shares in the last quarter. Assetmark Inc. purchased a new position in shares of Oric Pharmaceuticals in the third quarter worth about $37,000. Caitong International Asset Management Co. Ltd boosted its position in Oric Pharmaceuticals by 184.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after acquiring an additional 2,936 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Oric Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after acquiring an additional 977 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in Oric Pharmaceuticals during the 3rd quarter valued at about $60,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

Oric Pharmaceuticals Trading Up 1.2%

Shares of ORIC stock opened at $11.90 on Friday. Oric Pharmaceuticals has a 12-month low of $3.90 and a 12-month high of $14.93. The business’s 50 day moving average is $11.32 and its two-hundred day moving average is $11.24. The company has a market capitalization of $1.19 billion, a P/E ratio of -7.83 and a beta of 1.28.

Oric Pharmaceuticals (NASDAQ:ORIC) last posted its quarterly earnings data on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. On average, research analysts predict that Oric Pharmaceuticals will post -2.17 earnings per share for the current fiscal year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.